Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain

Patent metadata

Field	Value
Publication number	US-10214564-B2
Application number	US-201414766359-A
Country	US
Kind code	B2
Filing date	Feb 5, 2014
Priority date	Feb 6, 2013
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
(a) an effective amount of an isolated peptide, wherein the peptide consists of a protecting group and the amino acid sequence of SEQ ID NO:1, and exhibits an anti-bacterial or anti-fungal activity; and
(b) a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the peptide is characterized by having an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.

3. The composition of claim 1 , wherein the peptide exhibits an activity against colistin-resistant A. baumannii.

4. The composition of claim 1 , wherein the composition is formulated for topical, aerosol, oral, systemic intravenous, intraperitoneal, ocular, rectal, or inhalation administration.

5. A method of killing or inhibiting proliferation of a microorganism or treating a microbial infection in a subject, comprising:
administering to a subject in need thereof a pharmaceutical composition that contains (a) an effective amount of an isolated peptide and (b) a pharmaceutically acceptable carrier, the microorganism being a bacterium or fungus and the microbial infection being a bacterial or fungal infection, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.

6. The method of claim 5 , wherein the peptide consists of the sequence of SEQ ID NO: 1.

7. The method of claim 5 , wherein the peptide consists of the sequence of SEQ ID NO: 1 and a protecting group.

Assignees

• Academia Sinica

Inventors

• Shih Chiaho
• Chen Heng-Li
• Su Pei-Yi

Classifications

• A61K39/292 Primary

  Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C12N2730/10134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2730/10133

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title